These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30335259)

  • 1. [Basal insulin degludec - liraglutide fixed ratio combination (Xultophy®)].
    Scheen AJ; Mathieu C
    Rev Med Liege; 2018 Oct; 73(10):526-532. PubMed ID: 30335259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.
    Østergaard L; Frandsen CS; Dejgaard TF; Madsbad S
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):621-632. PubMed ID: 28349716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes.
    Harris K; Nealy KL
    Ann Pharmacother; 2018 Jan; 52(1):69-77. PubMed ID: 28799414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.
    Holst JJ; Buse JB; Rodbard HW; Linjawi S; Woo VC; Boesgaard TW; Kvist K; Gough SC
    J Diabetes Sci Technol; 2015 Oct; 10(2):389-97. PubMed ID: 26443290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
    Kaku K; Araki E; Tanizawa Y; Ross Agner B; Nishida T; Ranthe M; Inagaki N
    Diabetes Obes Metab; 2019 Dec; 21(12):2674-2683. PubMed ID: 31407845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
    Gough SC; Bode B; Woo V; Rodbard HW; Linjawi S; Poulsen P; Damgaard LH; Buse JB;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):885-93. PubMed ID: 25190523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?].
    Nauck M; Wilhelm B
    MMW Fortschr Med; 2017 Jun; 159(Suppl 5):7-15. PubMed ID: 28643293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.
    Price H; Blüher M; Prager R; Phan TM; Thorsted BL; Schultes B;
    Diabetes Obes Metab; 2018 Apr; 20(4):954-962. PubMed ID: 29205856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
    Buse JB; Vilsbøll T; Thurman J; Blevins TC; Langbakke IH; Bøttcher SG; Rodbard HW;
    Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Opin Drug Saf; 2017 Mar; 16(3):387-396. PubMed ID: 28150516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy.
    Kapitza C; Bode B; Ingwersen SH; Jacobsen LV; Poulsen P
    J Clin Pharmacol; 2015 Dec; 55(12):1369-77. PubMed ID: 25998481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.
    King AB; Philis-Tsimikas A; Kilpatrick ES; Langbakke IH; Begtrup K; Vilsbøll T
    Diabetes Technol Ther; 2017 Apr; 19(4):255-264. PubMed ID: 28282219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.
    Watada H; Kaneko S; Komatsu M; Agner BR; Nishida T; Ranthe M; Nakamura J
    Diabetes Obes Metab; 2019 Dec; 21(12):2694-2703. PubMed ID: 31423685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes.
    Greig SL; Scott LJ
    Drugs; 2015 Sep; 75(13):1523-34. PubMed ID: 26242767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
    Raya PM; Blasco FJA; Hunt B; Martin V; Thorsted BL; Basse A; Price H
    Diabetes Obes Metab; 2019 Jun; 21(6):1349-1356. PubMed ID: 30740861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
    Blumer I; Pettus JH; Santos Cavaiola T
    Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.
    Komatsu M; Watada H; Kaneko S; Ross Agner BF; Nishida T; Kaku K
    J Diabetes Investig; 2021 Sep; 12(9):1610-1618. PubMed ID: 33595901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.
    Kumar A
    Expert Opin Biol Ther; 2014 Jun; 14(6):869-78. PubMed ID: 24702171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.